Vaccine Company to be acquired by Lilly to advance best-in-class vaccine candidates for Epstein-Barr Virus and other infectious diseases

Lead program is a Phase 1-ready EBV vaccine candidate with potential to prevent infectious mononucleosis and the serious long-term conditions associated with EBV infection BETHESDA, Md., May 26, 2026 /PRNewswire/ -- Vaccine Company, Inc. (Vaccine Company), a privately held...